RPRatnakar Potla

Ratnakar Potla

*This is an algorithmically generated author record based on publicly available information.

Ratnakar Potla has a total of 98 co-authors. Here are the top co-authors by number of shared publications:

  • Donald Elliot Ingber

    Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA, USA

    5 shared publications
  • Benjamin D. Matthews

    Boston Children's Hospital and Harvard Medical School 1 Vascular Biology Program Boston, MA 02115 , USA

    4 shared publications
  • Ishwar S. Singh

    A Department of Medicine , University of Maryland School of Medicine , Baltimore , MD , USA

    4 shared publications
  • Mohan E. Tulapurkar

    A Department of Medicine , University of Maryland School of Medicine , Baltimore , MD , USA

    4 shared publications
  • Hao Wu

    Boston Children's Hospital and Harvard Medical School 1 Vascular Biology Program Boston, MA 02115 , USA

    3 shared publications
  • Hong Chen

    Boston Children's Hospital and Harvard Medical School 1 Vascular Biology Program Boston, MA 02115 , USA

    3 shared publications

Latest Publications

  • Open Access

    Complex in vitro models positioned for impact to drug testing in pharma: a review

    by Serah Kang, Eugene C Chen, Helen Cifuentes, Julia Y Co, Gabrielle Cole, Jessica Graham, Rebecca Hsia, Tomomi Kiyota, Jessica A Klein, Katharina T Kroll, et al.

    Recent years have seen the creation and popularization of various complex in vitro models (CIVMs), such as organoids and organs-on-chip, as a technology with the potential to reduce animal usage in pharma while also enhancing our ability to create safe and efficacious drugs for patients. Public awareness of CIVMs has increased, in part, due to the recent passage of the FDA Modernization Act 2.0. This visibility is expected to spur deeper investment in and adoption of such models. Thus, end-users and model developers alike require a framework to both understand the readiness of current models to enter the drug development process, and to assess upcoming models for the same. This review presents such a framework for model selection based on comparative -omics data (which we term model-omics), and metrics for qualification of specific test assays that a model may support that we term context-of-use (COU) assays. We surveyed existing healthy tissue models and assays for ten drug development-critical organs of the body, and provide evaluations of readiness and suggestions for improving model-omics and COU assays for each. In whole, this review comes from a pharma perspective, and seeks to provide an evaluation of where CIVMs are poised for maximum impact in the drug development process, and a roadmap for realizing that potential.


  • Top Cited Papers

    Modeling pulmonary cystic fibrosis in a human lung airway-on-a-chip

    by Roberto Plebani, Ratnakar Potla, Mercy Soong, Haiqing Bai, Zohreh Izadifar, Amanda Jiang, Renee N. Travis, Chaitra Belgur, Alexandre Dinis, Mark J. Cartwright, et al.


  • Open Access

    Molecular mapping of transmembrane mechanotransduction through the β1 integrin–CD98hc–TRPV4 axis

    by Ratnakar Potla, Mariko Hirano-Kobayashi, Hao Wu, Hong Chen, Akiko Mammoto, Benjamin D. Matthews, Donald E. Ingber

    One of the most rapid (less than 4 ms) transmembrane cellular mechanotransduction events involves activation of transient receptor potential vanilloid 4 (TRPV4) ion channels by mechanical forces transmitted across cell surface β1 integrin receptors on endothelial cells, and the transmembrane solute carrier family 3 member 2 (herein denoted CD98hc, also known as SLC3A2) protein has been implicated in this response. Here, we show that β1 integrin, CD98hc and TRPV4 all tightly associate and colocalize in focal adhesions where mechanochemical conversion takes place. CD98hc knockdown inhibits TRPV4-mediated calcium influx induced by mechanical forces, but not by chemical activators, thus confirming the mechanospecificity of this signaling response. Molecular analysis reveals that forces applied to β1 integrin must be transmitted from its cytoplasmic C terminus via the CD98hc cytoplasmic tail to the ankyrin repeat domain of TRPV4 in order to produce ultrarapid, force-induced channel activation within the focal adhesion.


  • PR1P Stabilizes VEGF and Upregulates Its Signaling to Reduce Elastase-induced Murine Emphysema

    by Avner Adini, Hao Wu, Duy T. Dao, Victoria H. Ko, Lumeng J. Yu, Amy Pan, Mark Puder, Selome Z. Mitiku, Ratnakar Potla, Hong Chen, et al.

    Emphysema is a progressive and fatal lung disease with no cure that is characterized by thinning, enlargement, and destruction of alveoli, leading to impaired gas exchange. Disease progression is due in part to dysregulation of VEGF (vascular endothelial growth factor) signaling in the lungs and increased lung-cell apoptosis. Here we asked whether PR1P (Prominin-1–derived peptide), a novel short peptide we designed that increases VEGF binding to endothelial cells, could be used to improve outcome in in vitro and in vivo models of emphysema. We used computer simulation and in vitro and in vivo studies to show that PR1P upregulated endogenous VEGF receptor-2 signaling by binding VEGF and preventing its proteolytic degradation. In so doing, PR1P mitigated toxin-induced lung-cell apoptosis, including from cigarette-smoke extract in vitro and from LPS in vivo in mice. Remarkably, inhaled PR1P led to significantly increased VEGF concentrations in murine lungs within 30 minutes that remained greater than twofold above that of control animals 24 hours later. Finally, inhaled PR1P reduced acute lung injury in 4- and 21-day elastase-induced murine emphysema models. Taken together, these results highlight the potential of PR1P as a novel therapeutic agent for the treatment of emphysema or other lung diseases characterized by VEGF signaling dysregulation.


  • Characterizing Host-Pathogen Interactions in Cystic Fibrosis Airway on a Chip Model

    by R. Potla, S. Gilpin, Z. Izadifar, M. Rhodas, Travis, M.J. Cartwright, R. Prantil-Baun, D.E. Ingber

  • Open Access

    AAV-mediated gene therapy targeting TRPV4 mechanotransduction for inhibition of pulmonary vascular leakage

    by Juan Li, Amy M. Wen, Ratnakar Potla, Ezekiel Benshirim, Ariel Seebarran, Maximilian A. Benz, Olivier Y. F. Henry, Benjamin D. Matthews, Rachelle Prantil-Baun, Sarah E. Gilpin, et al.

    Enhanced vascular permeability in the lungs can lead to pulmonary edema, impaired gas exchange, and ultimately respiratory failure. While oxygen delivery, mechanical ventilation, and pressure-reducing medications help alleviate these symptoms, they do not treat the underlying disease. Mechanical activation of transient receptor potential vanilloid 4 (TRPV4) ion channels contributes to the development of pulmonary vascular disease, and overexpression of the high homology (HH) domain of the TRPV4-associated transmembrane protein CD98 has been shown to inhibit this pathway. Here, we describe the development of an adeno-associated virus (AAV) vector encoding the CD98 HH domain in which the AAV serotypes and promoters have been optimized for efficient and specific delivery to pulmonary cells. AAV-mediated gene delivery of the CD98 HH domain inhibited TRPV4 mechanotransduction in a specific manner and protected against pulmonary vascular leakage in a human lung Alveolus-on-a-Chip model. As AAV has been used clinically to deliver other gene therapies, these data raise the possibility of using this type of targeted approach to develop mechanotherapeutics that target the TRPV4 pathway for treatment of pulmonary edema in the future.


  • Open Access

    Molecular mapping of transmembrane mechanotransduction through the β1 integrin-CD98hc-TRPV4 axis

    by Ratnakar Potla, Mariko Mariko Hirano-Kobayashi, Hao Wu, Hong Chen, Akiko Mammoto, Benjamin D. Matthews, Donald E. Ingber

    One of the most rapid (< 4 msec) transmembrane cellular mechanotransduction events involves activation of Transient Receptor Potential Vanilloid 4 (TRPV4) ion channels by mechanical forces transmitted across β1 integrin receptors in endothelial cells, and the transmembrane Solute Carrier family 3 member 2 (CD98hc) protein has been implicated in this response. Here, we show that β1 integrin, CD98hc, and TRPV4 all tightly associate and co-localize in focal adhesions where mechanochemical conversion takes place. CD98hc knock down inhibits TRPV4-mediated calcium influx induced by mechanical forces, but not by chemical activators, thus confirming the mechanospecificity of this signaling response. Molecular analysis revealed that forces applied to β1 integrin must be transmitted from its cytoplasmic C-terminus to the CD98hc cytoplasmic tail, and from there to the ankyrin repeat domain of TRPV4 in order to produce ultra-rapid, force-induced, channel activation within the focal adhesion. Abstract Figure: Graphical SUMMARY: A direct path of mechanical signal transfer between β1 integrin, CD98hc, and TRPV4 channels is identified that mediates ultra-rapid transmembrane mechanochemical conversion within focal adhesions.


  • Open Access

    Modeling radiation injury-induced cell death and countermeasure drug responses in a human Gut-on-a-Chip

    by Sasan Jalili-Firoozinezhad, Rachelle Prantil-Baun, Amanda Jiang, Ratnakar Potla, Tadanori Mammoto, James C. Weaver, Thomas C. Ferrante, Hyun Jung Kim, Joaquim M. S. Cabral, Oren Levy, et al.

    Studies on human intestinal injury induced by acute exposure to γ-radiation commonly rely on use of animal models because culture systems do not faithfully mimic human intestinal physiology. Here we used a human Gut-on-a-Chip (Gut Chip) microfluidic device lined by human intestinal epithelial cells and vascular endothelial cells to model radiation injury and assess the efficacy of radiation countermeasure drugs in vitro. Exposure of the Gut Chip to γ-radiation resulted in increased generation of reactive oxygen species, cytotoxicity, apoptosis, and DNA fragmentation, as well as villus blunting, disruption of tight junctions, and compromise of intestinal barrier integrity. In contrast, pre-treatment with a potential prophylactic radiation countermeasure drug, dimethyloxaloylglycine (DMOG), significantly suppressed all of these injury responses. Thus, the human Gut Chip may serve as an in vitro platform for studying radiation-induced cell death and associate gastrointestinal acute syndrome, in addition to screening of novel radio-protective medical countermeasure drugs.


  • Fibrinogen‐like protein‐2 causes deterioration in cardiac function in experimental autoimmune myocarditis rats through regulation of programmed death‐1 and inflammatory cytokines

    by Zhenzhong Zheng, Yinghui Yu, Ratnakar Potla, Yujing Wu, Hao Wu

    Summary: Programmed death‐1 (PD‐1) plays an important role in protecting against inflammation and myocyte damage in T‐cell‐mediated myocarditis. To understand whether fibrinogen‐like protein‐2 (FGL2) can affect the role of the PD‐1/PD‐L1 pathway in experimental autoimmune myocarditis (EAM), we investigated cardiac function in EAM rats over‐expressing FGL2. Over‐expression of FGL2 significantly decreased PD‐1 and deteriorated cardiac function in rats with autoimmune myocarditis. Histopathology revealed increased inflammatory cell infiltrate in EAM‐FGL2 rats compared with the control groups (EAM, EAM‐GFP and NC). Notably, transcription factor forkhead box P3 (Foxp3) and retinoic acid‐related orphan receptor γt (RORγt) protein and mRNA levels were statistically (P < 0·05) increased in EAM rats. We also found that interferon‐γ, interleukin‐6, interleukin‐17 and brain natriuretic peptide levels were profoundly increased in serum of FGL2 over‐expressing EAM rats. Hence, FGL2 plays an important role in the pathogenesis of autoimmune myocarditis that also involves the PD‐1/PD‐L1 pathway. Our findings may provide novel therapeutic targets for the treatment of immune‐induced heart injury.


  • Exposure to febrile-range hyperthermia potentiates Wnt signalling and epithelial–mesenchymal transition gene expression in lung epithelium

    by Ratnakar Potla, Mohan E. Tulapurkar, Irina G. Luzina, Sergei P. Atamas, Ishwar S. Singh, Jeffrey D. Hasday

    Background: As environmental and body temperatures vary, lung epithelial cells experience temperatures significantly different from normal core temperature. Our previous studies in human lung epithelium showed that: (i) heat shock accelerates wound healing and activates profibrotic gene expression through heat shock factor-1 (HSF1); (ii) HSF1 is activated at febrile temperatures (38–41 °C) and (iii) hypothermia (32 °C) activates and hyperthermia (39.5 °C) reduces expression of a subset of miRNAs that target protein kinase-Cα (PKCα) and enhance proliferation. Methods: We analysed the effect of hypo- and hyperthermia exposure on Wnt signalling by exposing human small airway epithelial cells (SAECs) and HEK293T cells to 32, 37 or 39.5 °C for 24 h, then analysing Wnt-3a-induced epithelial–mesenchymal transition (EMT) gene expression by qRT-PCR and TOPFlash reporter plasmid activity. Effects of miRNA mimics and inhibitors and the HSF1 inhibitor, KNK437, were evaluated. Results: Exposure to 39.5 °C for 24 h increased subsequent Wnt-3a-induced EMT gene expression in SAECs and Wnt-3a-induced TOPFlash activity in HEK293T cells. Increased Wnt responsiveness was associated with HSF1 activation and blocked by KNK437. Overexpressing temperature-responsive miRNA mimics reduced Wnt responsiveness in 39.5 °C-exposed HEK293T cells, but inhibitors of the same miRNAs failed to restore Wnt responsiveness in 32 °C-exposed HEK293T cells. Conclusions: Wnt responsiveness, including expression of genes associated with EMT, increases after exposure to febrile-range temperature through an HSF1-dependent mechanism that is independent of previously identified temperature-dependent miRNAs. This process may be relevant to febrile fibrosing lung diseases, including the fibroproliferative phase of acute respiratory distress syndrome (ARDS) and exacerbations of idiopathic pulmonary fibrosis (IPF).